Protective effect of Ulinastatin against murine models of sepsis: Inhibition of TNF-α and IL-6 and augmentation of IL-10 and IL-13

Experimental and Toxicologic Pathology

Volumn 64, Issue 6, 2012, Pages 543-547

  Cao, Yi Zhan ^a   Tu, Yan Yang ^a   Chen, Xiang ^b   Wang, Bo Liang ^a   Zhong, Yue Xia ^a   Liu, Ming Hua ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Department of surgery   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Interleukin 10; Interleukin 13; Interleukin 6; Sepsis; Tumor necrosis factor ; Ulinastatin

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 6; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CECUM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; IMMUNOMODULATION; INTESTINE BIOPSY; INTESTINE SURGERY; LIGATION; MALE; NONHUMAN; RAT; SEPSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPROTEINS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; MALE; RATS; RATS, WISTAR; SEPSIS; TRYPSIN INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MURINAE; RATTUS; RATTUS NORVEGICUS;

EID: 84864506615     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2010.11.011     Document Type: Article

References (36)

1. Allavena P., Piemonti L., Longoni D., Bernasconi S., Stoppacciaro A., Ruco L., et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998, 28:359-369.
2. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
3. Aosasa S., Ono S., Mochizuki H., Tsujimoto H., Ueno C., Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 2001, 15:101-105.
4. Baumhofer J.M., Beinhauer B.G., Wang J.E., Brandmeier H., Geissler K., Losert U., et al. Gene transfer with IL-4 and IL-13 improves survival in lethal endotoxemia in the mouse and ameliorates peritoneal macrophages immune competence. Eur J Immunol 1998, 28:610-615.
5. Blackwell T.S., Christman J.W. Sepsis and cytokines: a current status. Br J Anaesth 1996, 77:110-117.
6. Bone R.C. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996, 24:1125-1128.
7. Collighan N., Giannoudis P.V., Kourgeraki O., Perry S.L., Guillou P.J., Bellamy M.C. Interleukin 13 and inflammatory markers in human sepsis. Br J Surg 2004, 91:762-768.
8. Damas P., Ledoux D., Nys M., Vrindts Y., Groote D., Franchimont P., et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992, 215:356-362.
9. Dellinger R.P., Carlet J.M., Masur H., Gerlach H., Calandra T., Cohen J., et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32:858-873.
10. Ebong S., Call D., Nemzek J., Bolgos G., Newcomb D., Remick D. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun 1999, 67:6603-6610.
11. Ebong S.J., Call D.R., Bolgos G., Newcomb D.E., Granger J.I., O'Reily M., et al. Immunopathologic responses to non-lethal sepsis. Shock 1999, 12:118-126.
12. Friedman G., Jankowski S., Marchant A., Goldman M., Kahn R.J., Vincent J.L. Blood interleukin-10 levels parallel the severity of septic shock. J Crit Care 1997, 12:183-187.
13. Gardlund B., Sjolin J., Nilsson A., Roll M., Wickerts C.J., Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 1995, 172:296-301.
14. Girardin E., Grau G.E., Dayer J.M., Roux-Lombard P., Lambert P.H. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988, 319:397-400.
15. Glueck T., Opal S.M. Advances in sepsis therapy. Drugs 2004, 64:837-859.
16. Gogos C.A., Drosou E., Bassaris H.P., Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000, 181:176-180.
17. Hashimoto K., Nomura K., Nakano M., Sasaki T., Kurosawa H. Pharmacological intervention for renal protection during cardiopulmonary bypass. Heart Vessels 1993, 8:203-210.
18. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.
19. Hu G.D., Huo G.D., Cai S.X., Chen B., Chen Y.H. Effects of serum of the rats ventilated with high tidal volume on endothelial cell permeability and therapeutic effects of ulinastatin. Chin Med J 2006, 119:1374-1380.
20. Inoue K., Takano H., Shimada A., Yanagisawa R., Sakurai M., Yoshino S., et al. Urinary trypsin inhibitor protects against systemic inflammation induced by lip polysaccharide. Mol Pharmacol 2005, 67:673-680.
21. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. SCCM/ESICM/ACP/ATS/SIS international sepsis definitions conference. Intensive Care Med 2003, 29:530-538.
22. Liliensiek B., Weigand M.A., Bierhaus A., Nicklas W., Kasper M., Hofer S., et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004, 113:1641-1650.
23. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
24. Matsukawa A., Hogaboam C.M., Lukacs N.W., Lincoln P.M., Evanoff H.L., Strieter R.M., et al. Expression and contribution of endogenous IL-13 in an experimental model of sepsis. J Immunol 2000, 164:2738-2744.
25. Nishiyama T., Hirasaki A. Effect of ulinastatin on the elastase release in multiple injuries. Anesth Resus 1994, 30:77-80.
26. Ogawa M., Nishibe S., Mori T., Neumann S. Effect of human urinary trypsin inhibitor on granulocyte elastase activity. Res Commun Chem Pathol Pharmacol 1987, 55:271-274.
27. Parrillo J.E., Parker M.M., Natanson C., Suffredini A.F., Danner R.L., Cunnion R.E., et al. Septic shock in humans, advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Intern Med 1990, 113:227-240.
28. Pinsky M.R., Vincent J.L., Deviere J., Alegre M., Kahn R.J., Dupont E. Serum cytokine levels in human septic shock: relation to multiple-system organ dysfunction and mortality. Chest 1993, 103:565-575.
29. Pruitt J.H., Welborn M.B., Edwards P.D., Harward T.R., Seeger J.W., Martin T.D., et al. Soluble interleukin-1 type-II receptor concentrations in postoperative patients and in patients with sepsis syndrome. Blood 1996, 87:3282-3288.
30. Remick D.G., Bolgos G.R., Siddiqui J., Shin J., Nemzek J.A. Six at six: interleukin-6 measured 6h after the initiation of sepsis predicts mortality over 3 days. Shock 2002, 17:463-467.
31. Sands K.E., Bates D.W., Lanken P.N., Graman P.S., Hibberd P.L., Kahn K.L., et al. Epidemiology of sepsis syndrome in 8 academic medical centers. J Am Med Assoc 1997, 278:234-240.
32. Sato K., Nagayama H., Tadokoro K., Juji T., Takahashi T.A. Interleukin 13 is involved in functional maturation of human peripheral blood monocyte-derived dendritic cells. Exp Hematol 1999, 27:326-336.
33. Sato Y., Ishikawa S., Otaki A. Induction of acute-phase reactive substances during open-heart surgery and efficacy of ulinastatin. Inhibiting cytokines and postoperative organ injury. Jpn J Thorac Cardiovasc Surg 2000, 48:428-434.
34. Van Zee K.J., Kohno T., Fischer E., Rock C.S., Moldawer L.L., Lowry S.F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A 1992, 89:4845-4849.
35. Waage A., Halstensen A., Espevick T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987, 1:355-357.
36. Yu M., Shao D.B., Liu J., Zhu J., Zhang Z., Xu J. Effects of ketamine on levels of cytokines, NF-κB and TLRs in rat intestine during CLP-induced sepsis. Int Immunopharmacol 2007, 7:1076-1082.